Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Leyvraz

Showing results (61-70 of 108) with videos related to

Pageof 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapyS Leyvraz, V Spataro, J Bauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow TransplantationS Leyvraz, L Perey, G Rosti, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
Rapidly alternating combination of cisplatin-based chemotherapy and hyperfractionated accelerated radiotherapy in split course for stage IIIA and stage IIIB non-small cell lung cancer: results of a phase I-II study by the GOTHA group. Group d'Oncologie Thoracique des Régions AlpinesP Alberto, R O Mirimanoff, B Mermillod, et al.
Revue Medicale Suisse|July 12, 2008
[Systemic treatment of metastatic colorectal cancer]M Montemurro, L Achtari, A Röth, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 20, 1998
Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapyR J Salmon, C Levy, C Plancher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1995
Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK)R A Joss, P Alberto, C Hürny, et al.
British Journal of Cancer|October 1, 1990
Elevated CA125 levels in patients with metastatic breast carcinomaL Perey, D F Hayes, C Tondini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82H J Senn, R Maibach, M Castiglione, et al.
British Journal of Cancer|May 14, 2008
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerabilityN Widmer, L A Decosterd, S Leyvraz, et al.
Schweizerische Medizinische Wochenschrift|February 11, 1995
[Participation in multicenter studies as quality control in the therapy of Hodgkin disease: an interim report]A Lohri, S Leyvraz, T Cerny, et al.
Pageof 11

Showing results (61-70 of 108) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapyS Leyvraz, V Spataro, J Bauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow TransplantationS Leyvraz, L Perey, G Rosti, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
Rapidly alternating combination of cisplatin-based chemotherapy and hyperfractionated accelerated radiotherapy in split course for stage IIIA and stage IIIB non-small cell lung cancer: results of a phase I-II study by the GOTHA group. Group d'Oncologie Thoracique des Régions AlpinesP Alberto, R O Mirimanoff, B Mermillod, et al.
Revue Medicale Suisse|July 12, 2008
[Systemic treatment of metastatic colorectal cancer]M Montemurro, L Achtari, A Röth, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 20, 1998
Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapyR J Salmon, C Levy, C Plancher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1995
Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK)R A Joss, P Alberto, C Hürny, et al.
British Journal of Cancer|October 1, 1990
Elevated CA125 levels in patients with metastatic breast carcinomaL Perey, D F Hayes, C Tondini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82H J Senn, R Maibach, M Castiglione, et al.
British Journal of Cancer|May 14, 2008
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerabilityN Widmer, L A Decosterd, S Leyvraz, et al.
Schweizerische Medizinische Wochenschrift|February 11, 1995
[Participation in multicenter studies as quality control in the therapy of Hodgkin disease: an interim report]A Lohri, S Leyvraz, T Cerny, et al.
Pageof 11